N -(正丁基)脱氧半乳糖霉素;(2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)piperidine-3,4,5-triol;N-(But-1-yl)deoxygalactonojirimycin, (2R,3S,4R,5S)-1-(But-1-yl)-2-(hydroxymethyl)-3
1. Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21. 2. R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.